Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & DevelopmentBusiness Wire • 07/19/21
Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE)Business Wire • 06/09/21
Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO)Business Wire • 06/08/21
Why Is Arena Pharmaceuticals, Inc. (ARNA) Down 2.8% Since Last Earnings Report?Zacks Investment Research • 06/04/21
Arena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable InvestmentsBusiness Wire • 06/03/21
Arena Pharmaceuticals Earns Prime Status from ISS ESG, a Leading Rating Agency for Sustainable InvestmentsBusiness Wire • 05/12/21
Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/06/21
Arena Pharmaceuticals, Inc. (ARNA) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/05/21
Arena Reports First Quarter Financial Results with Strong Cash Position and Continued Progress on Pipeline Over the QuarterBusiness Wire • 05/05/21
Arena Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Corporate Update on May 5Business Wire • 04/28/21
Arena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academy of Dermatology VMXBusiness Wire • 04/23/21
Arena Pharmaceuticals Releases Second Annual Environmental, Social and Governance (ESG) ReportBusiness Wire • 04/19/21
Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial During Late-Breaking Research Session at American Academy of Dermatology Virtual Meeting ExperienceBusiness Wire • 04/19/21